Predicting p53 Status in IDH-Mutant Gliomas Using MRI-Based Radiomic Model.

OBJECTIVES

Accurate and noninvasive detection of p53 status in isocitrate dehydrogenase mutant (IDH-mt) glioma is clinically meaningful for molecular stratification of glioma, yet it remains challenging. We aimed to investigate the diagnostic efficacy of radiomics utilizing pre-surgery contrast-enhanced T1-weighted imaging (CE-T1WI) for predicting p53 status in IDH-mt gliomas.

METHODS

A total of seventy-eight patients with pathologically confirmed IDH-mutant glioma were admitted to our institution between January 2011 and October 2018. For each patient, three types of volumes of interest (VOIs) were segmented: (i) VOI: the entire tumor (including the necrotic area within the tumor); (ii) VOI: the peritumoral edema; (iii) VOI: the entire tumor and peritumoral edema. A total of 962 radiomic features were extracted for each VOI, followed by feature selection and modeling (Rad_VOI, Rad_VOI, and Rad_VOI models) using machine learning algorithms. A nomogram was developed to integrate significant clinical factors and radiomic predictors for p53 status prediction. Akaike Information Criterion (AIC) was leveraged as the stopping rule. The predictive performance of the models was evaluated using receiver operating characteristic (ROC) curve analysis.

RESULTS

The VOI model, which included the eight best-performing features, demonstrated the highest predictive performance among the three VOI-based models, with AUCs of 0.811 (95% CI: 0.782-0.840) and 0.810 (95% CI: 0.786-0.834) in the training and validation cohorts, respectively. Age was identified as the only significant clinical factor and was combined with the Rad-scores from VOI, VOI, and VOI to construct a clinical-radiomics nomogram with the most notable discriminative ability for p53 status (AIC = -120.19). The AUCs for this nomogram were 0.969 (95% CI: 0.942-0.996) in the training cohort and 0.929 (95% CI: 0.898-0.960) in the validation cohort.

CONCLUSION

The CE-T1WI-based radiomic model can noninvasively predict p53 mutation status in IDH-mt gliomas. The textural differences of peritumoral edema may more accurately reflect the underlying tumor heterogeneity associated with p53 status.